Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Introduction: Stereotactic ablative radiotherapy for prostate cancer allows high doses of radiotherapy to be delivered with high precision over a short course of treatment [1]. Here, we report the clinical outcomes at 18 month follow-up in a prospective safety and feasibility study where patients were treated with Rapidarc and flattening filter free (FFF).
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. FiguresAim: To determine whether the delivered dose on treatment is in agreement of the planned dose to organs at risk. To access this article, please choose from the options below Purchase access to this article Claim Access If you are a current subscriber with Society Membership or an Account Number, claim your access now.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
